Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Up 5.60%
As of Thursday, August 06, Xilio Therapeutics, Inc.’s XLO share price has surged by 5.60%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Up 5.42%
As of Thursday, July 23, Xilio Therapeutics, Inc.’s XLO share price has surged by 5.42%, which has investors questioning if this is right time to sell.Michael Rose
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 31.64%
As of Monday, June 02, Xilio Therapeutics, Inc.’s XLO share price has dipped by 31.64%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 31.43%
As of Monday, June 02, Xilio Therapeutics, Inc.’s XLO share price has dipped by 31.43%, which has investors questioning if this is right time to buy.Tudor Pop
Why Xilio Therapeutics, Inc.’s (XLO) Stock Is Down 16.08%
As of Wednesday, May 14, Xilio Therapeutics, Inc.’s XLO share price has dipped by 16.08%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | XLO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $60.7 | $292.6 | 17% |
|
| Shares Out (Mil) | 19.4 | 54.4 | 29% |
|
| Institutional Ownership | 76.2% | 93.2% | 46% |
|
| Float (Mil) | 3.4 | 40.2 | 9% |
|
| Beta | -0.12 | 0.94 | 4% |
|
| Avg Daily Volume (000s) | 12 | 544 | 18% |
|
| Price Change (52-week) |
(0.7%) | 59.7% | 44% |
|
| Growth | XLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 8.7% | (10.1%) | 53% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.1% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $64 | $37 | 22% |
|
| Net Income (TTM) (Mil) | ($22) | ($43) | 23% |
|
| EPS (TTM) | ($3.317) | ($1.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $2 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | ($75) | $164 | 1% |
|
| Valuation | XLO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.84 | 2.83 | 16% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | XLO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 83.2% | 64.2% | 90% |
|
| Net Margin | (34.1%) | (75.9%) | 14% |
|
| ROA | (15.2%) | (47.5%) | 22% |
|
| ROE | (55.0%) | (55.0%) | 14% |
|
| Liabilities to Assets | 53.2% | 29.6% | 46% |
|
| F-Score | 4 | 3 | 33% |
|
Xilio Therapeutics, Inc. did not pass any screens on 8/21/2026.
